Research & Literature

Incidence of adult T-cell leukemia/lymphoma in nonendemic areas.

Yoshida N, Chihara D

Current treatment options in oncology 2015; (16(2)):7 doi:10.1007/s11864-014-0321-5.

Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma.

Yoshida N, Imaizumi Y, Utsunomiya A, et al.

Journal of clinical and experimental hematopathology : JCEH 2015; (55(1)):13-6 doi:10.3960/jslrt.55.13.

How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

Bangham CR, Ratner L

Current opinion in virology 2015; (14()):93-100.

Optimizing Management of Patients with Adult T Cell Leukemia-Lymphoma.

Yared JA, Kimball AS

Cancers 2015; (7(4)):2318-29 doi:10.3390/cancers7040893.

HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).

Yasuma K, Yasunaga J, Takemoto K, et al.

PLoS pathogens 2016; (12(1)):e1005372 doi:10.1371/journal.ppat.1005372.

HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells.

Kawatsuki A, Yasunaga JI, Mitobe Y, et al.

Oncogene 2016; (35(34)):4509-17 doi:10.1038/onc.2015.510.

Severe cytomegalovirus colitis with highly elevated sIL-2R mimicking aggressive transformation of adult T-cell lymphoma.

Tabata R, Tabata C, Yasumizu R

Antiviral therapy 2016; (21(7)):641-645 doi:10.3851/IMP3050.

Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.

Sugio T, Kato K, Aoki T, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016; (22(9)):1608-1614 doi:10.1016/j.bbmt.2016.05.017.

HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.

Giam CZ, Semmes OJ

Viruses 2016; (8(6)).

Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping.

Kagdi HH, Demontis MA, Fields PA, et al.

Cancer medicine 2017; (6(1)):298-309 doi:10.1002/cam4.928.

Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.

Sekine M, Kubuki Y, Kameda T, et al.

European journal of haematology 2017; (98(5)):501-507 doi:10.1111/ejh.12863.

Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil.

Oliveira PD, Gomes Í, Souza VH, et al.

Revista brasileira de hematologia e hemoterapia 2017; (39(1)):13-19 doi:10.1016/j.bjhh.2016.09.012.

Primary cutaneous smoldering adult T-cell leukemia/ lymphoma.

Gittler J, Martires K, Terushkin V, et al.

Dermatology online journal 2016; (22(12)).

Adult T-cell Leukemia/Lymphoma: A Problem Abroad and at Home.

Dittus C, Sloan JM

Hematology/oncology clinics of North America 2017; (31(2)):255-272 doi:10.1016/j.hoc.2016.11.005.

Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation.

Fuji S, Yamaguchi T, Inoue Y, et al.

Haematologica 2017; (102(7)):1258-1265 doi:10.3324/haematol.2017.164996.

Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.

Nasr R, Marçais A, Hermine O, Bazarbachi A

Methods in molecular biology (Clifton, N.J.) 2017; (1582()):197-216 doi:10.1007/978-1-4939-6872-5_15.

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.

Katsuya H, Shimokawa M, Ishitsuka K, et al.

Blood 2017; (130(1)):39-47 doi:10.1182/blood-2017-01-757542.

Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.

Winsett FT, Lewis DJ, Duvic M

Expert review of hematology 2017; (10(9)):757-760 doi:10.1080/17474086.2017.1361819.

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

Hurabielle C, Leboeuf C, Ram-Wolff C, et al.

The British journal of dermatology 2018; (179(1)):197-199 doi:10.1111/bjd.16322.

Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.

Masuda Y, Tatsuno K, Kitano S, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(9)):1456-1460 doi:10.1111/jdv.14797.

Adult T-cell Leukemia/Lymphoma as a Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis.

Takajo I, Umekita K, Ikei Y, et al.

Internal medicine (Tokyo, Japan) 2018; (57(14)):2071-2075 doi:10.2169/internalmedicine.0308-17.

Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States.

Malpica L, Pimentel A, Reis IM, et al.

Blood advances 2018; (2(6)):607-620 doi:10.1182/bloodadvances.2017011106.

Human T-lymphotropic virus 1 associated with adult T-cell leukemia/lymphoma.

James T, Fivenson D, Cotton J

Cutis 2018; (102(1)):E4-E7.

Adult T-Cell Leukemia-Lymphoma.

Munakata W, Tobinai K

Cancer treatment and research 2019; (176()):145-161 doi:10.1007/978-3-319-99716-2_7.

Prognostic impact of soluble interleukin-2 receptor level profiling in smoldering type adult T-cell leukemia-lymphoma.

Kubota A, Nakano N, Tokunaga M, et al.

Hematological oncology 2019; (37(2)):223-225 doi:10.1002/hon.2574.

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

Cook LB, Fuji S, Hermine O, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(8)):677-687 doi:10.1200/JCO.18.00501.

Crusted (Norwegian) scabies as a strong marker of adult T-cell leukemia/lymphoma in HTLV-1 infection.

Bimbi C, Brzezinski P, Sokolowska-Wojdylo M

Clinical case reports 2019; (7(3)):474-476 doi:10.1002/ccr3.1983.

Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report.

Nishikawa Y, Mochida K, Kubo T, et al.

Clinical case reports 2019; (7(5)):1057-1061 doi:10.1002/ccr3.2155.

Cutaneous manifestations of adult T-cell leukemia/lymphoma.

Miyashiro D, Sanches JA

Seminars in diagnostic pathology 2020; (37(2)):81-91 doi:10.1053/j.semdp.2019.07.010.

CD4+ CADM1+ cell percentage predicts disease progression in HTLV-1 carriers and indolent adult T-cell leukemia/lymphoma.

Makiyama J, Kobayashi S, Watanabe E, et al.

Cancer science 2019; (110(12)):3746-3753 doi:10.1111/cas.14219.

Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma.

Utsunomiya A

Frontiers in microbiology 2019; (10()):2235 doi:10.3389/fmicb.2019.02235.

Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.

Shah UA, Shah N, Qiao B, et al.

Cancer 2020; (126(3)):567-574 doi:10.1002/cncr.32556.

NF-κB and MicroRNA Deregulation Mediated by HTLV-1 Tax and HBZ.

Fochi S, Ciminale V, Trabetti E, et al.

Pathogens (Basel, Switzerland) 2019; (8(4)) doi:10.3390/pathogens8040290.

HTLV-1 bZIP factor: the key viral gene for pathogenesis.

Matsuoka M, Mesnard JM

Retrovirology 2020; (17(1)):2 doi:10.1186/s12977-020-0511-0.

Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.

Takeuchi M, Miyoshi H, Nakashima K, et al.

Annals of hematology 2020; (99(5)):1093-1098 doi:10.1007/s00277-020-03967-x.

Lymphomatous adult T cell leukaemia/lymphoma with anaplastic morphology in a country non-endemic for HTLV: a mimicker of anaplastic large cell lymphoma.

Li CH, Chang ST, Wu HC, et al.

Histopathology 2020; (77(4)):678-680 doi:10.1111/his.14173.

Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma.

Tsukasaki K, Marçais A, Nasr R, et al.

Frontiers in microbiology 2020; (11()):1207 doi:10.3389/fmicb.2020.01207.

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.

Muranushi H, Shindo T, Hishizawa M, et al.

Bone marrow transplantation 2021; (56(1)):155-166 doi:10.1038/s41409-020-00996-y.

Resolution of bone, cutaneous, and muscular involvement after haploidentical hematopoietic stem cell transplantation followed by post-transplant cyclophosphamide in adult T-cell leukemia/lymphoma.

Iioka F, Tanabe H, Honjo G, et al.

Clinical case reports 2020; (8(8)):1553-1559 doi:10.1002/ccr3.2925.

Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.

Imaizumi Y, Iwanaga M, Nosaka K, et al.

Cancer science 2020; (111(12)):4567-4580 doi:10.1111/cas.14658.

Primary bone adult T cell lymphoma with multiple skeletal lesions and debilitating painful osteolysis: a case report.

Kato H, Koga M, Kobayashi H, et al.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2021; (32(5)):1013-1017 doi:10.1007/s00198-020-05720-6.

Peripheral lymphocytosis presenting as EBV/HTLV-1 co-infection adult T-cell leukemia.

Kasinathan G, Sathar J

Hematology, transfusion and cell therapy 2022; (44(2)):279-283 doi:10.1016/j.htct.2020.09.146.

The E3/E4 ubiquitin conjugation factor UBE4B interacts with and ubiquitinates the HTLV-1 Tax oncoprotein to promote NF-κB activation.

Mohanty S, Han T, Choi YB, et al.

PLoS pathogens 2020; (16(12)):e1008504 doi:10.1371/journal.ppat.1008504.

Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma.

Yoshida N, Yamada K, Ohshima K

Cancer science 2021; (112(4)):1339-1347 doi:10.1111/cas.14849.

Diagnosis and management of adult T-cell leukemia/lymphoma.

Ishitsuka K

Seminars in hematology 2021; (58(2)):114-122 doi:10.1053/j.seminhematol.2021.02.005.

HTLV-1-Associated Lymphoma Presented as Massive Lymphadenopathy.

Chen PT, Onukogu D, Gotlieb G, et al.

Journal of investigative medicine high impact case reports 2021; (9()):23247096211013235 doi:10.1177/23247096211013235.

Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.

Malpica L, Enriquez DJ, Castro DA, et al.

JCO global oncology 2021; (7()):1151-1166 doi:10.1200/GO.21.00084.

Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.

Guery R, Suarez F, Lanternier F, et al.

Annals of hematology 2021; (100(11)):2813-2824 doi:10.1007/s00277-021-04622-9.

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.

Tanaka N, Mori S, Kiyotani K, et al.

Haematologica 2022; (107(10)):2418-2431 doi:10.3324/haematol.2021.280352.

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.

Kameda T, Shide K, Tahira Y, et al.

Viruses 2022; (14(4)) doi:10.3390/v14040710.

Hypercalcemia as the Initial Presentation of Acute T-cell Leukemia/Lymphoma.

Ramachandran V

Cureus 2022; (14(3)):e23705 doi:10.7759/cureus.23705.

Genetic Alterations in Adult T-Cell Leukemia/Lymphoma: Novel Discoveries with Clinical and Biological Significance.

Sakihama S, Karube K

Cancers 2022; (14(10)) doi:10.3390/cancers14102394.

Adult T cell leukaemia/lymphoma (ATL) in pregnancy: A UK case series.

Motedayen Aval L, Boullier M, Lyall H, et al.

EJHaem 2021; (2(1)):131-135 doi:10.1002/jha2.142.

Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.

Imaizumi Y, Iwanaga M, Nosaka K, et al.

International journal of hematology 2023; (117(2)):206-215 doi:10.1007/s12185-022-03473-y.

Advances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma.

Phillips AA

Current opinion in virology 2023; (58()):101289 doi:10.1016/j.coviro.2022.101289.

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.

Kameda T, Kataoka K, Kamiunten A, et al.

Haematologica 2023; (108(8)):2178-2191 doi:10.3324/haematol.2022.281510.

Prognostic analysis of smoldering ATLL with skin eruptions based on genomic aberrations.

Mochida K, Nakahata S, Suzuki Y, et al.

Journal of dermatological science 2023; (109(2)):80-88 doi:10.1016/j.jdermsci.2023.02.001.

Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma.

Katsuya H

International journal of hematology 2023; (117(4)):512-522 doi:10.1007/s12185-023-03572-4.

An update on the developments in the treatment of adult T-cell leukemia-lymphoma: current knowledge and future perspective.

Makiyama J, Ishitsuka K, Munakata W, et al.

Japanese journal of clinical oncology 2023; (53(12)):1104-1111 doi:10.1093/jjco/hyad108.

Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review.

Letafati A, Soheili R, Norouzi M, et al.

Medical oncology (Northwood, London, England) 2023; (40(10)):295 doi:10.1007/s12032-023-02166-8.

Human T-cell Lymphotropic Virus Type 1 (HTLV-1)-Associated Adult T-cell Leukemia/Lymphoma in a Patient Previously Treated for Strongyloidiasis.

Basharat A, Anwar MY, Sulh M, et al.

Cureus 2023; (15(10)):e47283 doi:10.7759/cureus.47283.

Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation.

Trotta GE, Ciangola G, Cerroni I, et al.

Current research in translational medicine 2024; (72(3)):103452 doi:10.1016/j.retram.2024.103452.

Clinical characteristics, genetic alterations, and prognosis of adult T-cell leukemia/lymphoma: an 11-year multicenter retrospective study in China.

Luo L, Chen Y, Wu Z, et al.

American journal of cancer research 2024; (14(4)):1649-1661 doi:10.62347/RARP1733.

Chemotherapy and allo-HSCT for young patients with aggressive ATL.

Fuji S

Leukemia research 2024; (147()):107596 doi:10.1016/j.leukres.2024.107596.

Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.

Zinzani PL, Izutsu K, Mehta-Shah N, et al.

The Lancet. Oncology 2024; (25(12)):1602-1613 doi:10.1016/S1470-2045(24)00503-5.

Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance.

Miyazaki T, Uno S, Fujimori H, Motegi Y

International journal of hematology 2025; (121(1)):79-88 doi:10.1007/s12185-024-03864-3.

Clinical and therapeutic significance of genetic profiling in adult T-cell leukemia/lymphoma.

Kogure Y, Kataoka K

Leukemia research 2025; (151()):107676 doi:10.1016/j.leukres.2025.107676.

Improving outcome prediction in indolent ATL by subdividing intermediate risk into low- and high-intermediate groups.

Fuji S, Tokunaga M, Utsunomiya A, et al.

Annals of hematology 2025; (104(4)):2429-2436 doi:10.1007/s00277-025-06319-9.

Risk Factors for Malignant Progression to Adult-T-Cell Leukemia/Lymphoma in HTLV-1 Carriers: A Systematic Review of Cohort and Case-Control Studies.

Estrada-Grossmann JM, Alarcón-Braga EA, Salazar-Valdivia FE, et al.

Clinical lymphoma, myeloma & leukemia 2025; (25(10)):720-729.e2 doi:10.1016/j.clml.2025.04.013.

The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.

Kgatle M, Mbambara S, Khoza L, et al.

Frontiers in microbiology 2025; (16()):1602497 doi:10.3389/fmicb.2025.1602497.

A comprehensive assessment using multiple factors based on HAS-Flow analysis predicts ATL development and progression.

Nakamura H, Watanabe T, Sato A, et al.

Scientific reports 2025; (15(1)):26618 doi:10.1038/s41598-025-10822-4.

Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies.

Vasconez-Gonzalez J, Suárez-Sangucho IA, Acosta-Muñoz E, et al.

Frontiers in cellular and infection microbiology 2025; (15()):1587802 doi:10.3389/fcimb.2025.1587802.

Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.

López-Pereira P, Bazarbachi A, Marçais A, et al.

Bone marrow transplantation 2026; (61(3)):341-346 doi:10.1038/s41409-025-02783-z.

Epidemiology of adult T-cell leukemia/lymphoma (ATL) in people living with HTLV-1: A 30-year study in Peru.

Garrido-Pinzás G, Valenzuela B, González-Lagos E, et al.

PLoS neglected tropical diseases 2026; (20(2)):e0014010 doi:10.1371/journal.pntd.0014010.

Hypercalcemia and Flower Cells on Peripheral Smear Revealing Human T-lymphotropic Virus Type 1 (HTLV-1)-Associated Adult T-cell Leukemia/Lymphoma.

Williams JM, Clark B, Verdecia J, An J

Cureus 2026; (18(2)):e103225 doi:10.7759/cureus.103225.